BioInvent International AB (BOVNF) Financial Statements
BioInvent International AB Financial Overview
BioInvent International AB's market cap is currently $36.36M. The company's EPS TTM is $-7.40; its P/E ratio is -0.73; BioInvent International AB is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 226.50M | $ 44.69M | $ 71.46M | $ 326.13M | $ 19.38M |
| Gross Profit | $ 226.50M | $ 44.69M | $ 71.46M | $ 326.13M | $ 19.38M |
| Operating Income | $ -351.39M | $ -471.06M | $ -369.94M | $ -50.92M | $ -278.35M |
| EBITDA | $ -331.52M | $ -409.38M | $ -312.71M | $ -27.13M | $ -263.32M |
| Net Income | $ -332.86M | $ -429.38M | $ -330.30M | $ -34.09M | $ -278.96M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 592.75M | $ 867.16M | $ 1.07B | $ 1.02B | $ 1.08B |
| Total Assets | $ 671.20M | $ 989.24M | $ 1.40B | $ 1.71B | $ 1.45B |
| Total Debt | $ 9.68M | $ 17.41M | $ 23.24M | $ 26.96M | $ 28.37M |
| Net Debt | $ -346.49M | $ -417.41M | $ -236.30M | $ -488.08M | $ -882.39M |
| Total Liabilities | $ 113.59M | $ 103.42M | $ 90.45M | $ 106.09M | $ 80.32M |
| Stockholders' Equity | $ 557.62M | $ 885.82M | $ 1.31B | $ 1.61B | $ 1.37B |
| Cash Flow | |||||
| Free Cash Flow | $ -255.01M | $ -390.50M | $ -355.00M | $ -53.60M | $ -259.10M |
| Operating Cash Flow | $ -247.75M | $ -380.47M | $ -341.69M | $ -41.23M | $ -245.84M |
| Investing Cash Flow | $ 180.13M | $ 564.35M | $ 59.68M | $ -628.85M | $ -467.54M |
| Financing Cash Flow | $ -8.98M | $ -8.46M | $ 23.14M | $ 273.49M | $ 894.87M |
Currency in SEK